STAT+: Biosecure didn’t stop China’s rise in biotech. Some lawmakers want to do more

Congress passed a bill last year to restrict U.S. pharmaceutical and biotechnology companies' business dealings with Chinese firms, but many lawmakers are seeking further measures. These efforts aim to counter the growth of Chinese biopharma companies through additional legislative and regulatory actions. Federal health officials are also working to facilitate operations for companies within the U.S. Bobby McMillin, a partner at Arnold Porter, stated that the concerns have not been fully addressed, indicating a continued push for more stringent policies. The impetus for these actions stems from concerns over national security and intellectual property, particularly as China's biotechnology sector continues its rapid expansion. Lawmakers are exploring various avenues, including increased scrutiny of foreign investment and stricter export controls on sensitive technologies. The debate highlights a growing tension between fostering international collaboration in scientific research and safeguarding domestic industries and national interests. The ongoing legislative discussions suggest a sustained focus on the competitive landscape of the global biotechnology market and the strategic implications of China's advancements in the field.